-
Scandic Trust Group strengthens sales network with First Idea Consultant
-
Tight UK security ahead of match against Israeli club
-
Ethiopia's Afar region says attacked by Tigray forces
-
Nancy Pelosi, Democratic giant, Trump foe, first woman House speaker, to retire
-
Israel strikes Hezbollah targets in Lebanon
-
Burger strikes as South Africa restrict Pakistan to 269-9 in second ODI
-
Stocks slip as investors weigh earnings, tariffs
-
Police say 19 held after raid at Swedish start-up Stegra to be deported
-
Kante returns as France seek to clinch World Cup berth
-
Marcus Smith starts at full-back as England ring changes for Fiji
-
Kolisi 100th Test 'no distraction' for Erasmus' South Africa
-
Teetering Belgian government given more time to agree budget
-
Merz backs EU plan to protect steel sector from Chinese imports
-
New Zealand make Scotland changes after Barrett brothers' injuries
-
'Roy of the Rovers story' -- Farrell handed Ireland debut for Japan Test
-
Stones backs Man City team-mate Foden to pose England dilemma for Tuchel
-
Djokovic to face Alcaraz in ATP Finals groups
-
Facing climate 'overshoot', world heads into risky territory
-
Springbok skipper Kolisi to play 100th Test against France
-
Typhoon Kalmaegi hits Vietnam after killing 140 in Philippines
-
Bank of England leaves rate unchanged before UK budget
-
Germany recall Sane, hand El Mala debut for World Cup qualifers
-
India thump Australia to take 2-1 lead in T20 series
-
Cameroon's Biya, world's oldest president, sworn in for 8th term
-
Flick holding firm on Barca high line despite defensive woes
-
Battered US businesses eye improved China trade at Shanghai expo
-
France opt for Le Garrec as Dupont replacement for 'best team ever' South Africa
-
Drugmaker AstraZeneca profit jumps as US business grows
-
'Vibe coding' named word of the year by Collins dictionary
-
Vietnam evacuates thousands from coast ahead of Typhoon Kalmaegi
-
European stocks fall after gains in Asia, US
-
MotoGP legend Agostini admires Marc Marquez's 'desire to win'
-
Nepal searches for avalanche victims
-
Hezbollah rejects any negotiations between Lebanon and Israel
-
Chapman blitz leads Black Caps to tight T20 victory over West Indies
-
France urges EU to sanction Shein platform
-
France opt for Le Garrec as Dupont replacement for South Africa Test
-
Turmoil in tiaras at Miss Universe pageant in Thailand
-
Probe into Thales defence group looking at Indonesian contract
-
US to cancel flights as longest govt shutdown drags on
-
Home in Nigeria, ex-refugees find themselves in a war zone
-
Doncic's Lakers hold off Wembanyama's Spurs, Blazers silence Thunder
-
For Turkey's LGBTQ community, draft law sparks existential alarm
-
Musk's $1 trillion pay package to face Tesla shareholder vote
-
Tonga rugby league star out of intensive care after seizure
-
Argentine ex-president Kirchner goes on trial in new corruption case
-
Dams, housing, pensions: Franco disinformation flourishes online
-
Endo returns as Japan look to build on Brazil win
-
Franco captivates young Spaniards 50 years after death
-
German steel industry girds for uncertain future
US approves first at-home cervical cancer screening device
The US Food and Drug Administration has approved an at-home cervical cancer screening tool as an alternative to Pap smears by a gynecologist, the company behind the device said Friday.
The "Teal Wand" -- a self-collection vaginal swab shaped like a tampon and developed by Teal Health -- will be available online for individuals aged 25 to 65 who are at average risk for cervical cancer.
Users request a kit online, have a brief visit with a telehealth provider to gauge eligibility and then the kit is prescribed. They then collect the sample and ship it to a lab for analysis.
Cervical cancer, which affects the lower part of the uterus, is diagnosed in about 0.6 percent of women. Although HPV vaccination and regular screening are highly effective at preventing the disease, more than one in four women fall behind on routine appointments.
"When we make care easier to get, we help women stay healthy, for themselves and for the people who rely on them every day," Teal Health CEO Kara Egan said in a statement.
The Teal Wand tests for high-risk strains of human papillomavirus (HPV), the primary cause of cervical cancer.
A large clinical trial found its accuracy comparable to a traditional Pap smear, which requires a speculum and is often cited as a barrier to screening due to discomfort.
Most sexually active people will contract HPV at some point, though only a small fraction develop cancer.
Teal Health did not disclose pricing but said it is in talks with insurers to ensure affordability. The product will launch first in California in June.
F.Schneider--AMWN